<code id='4E3D526BFC'></code><style id='4E3D526BFC'></style>
      • <acronym id='4E3D526BFC'></acronym>
      <center id='4E3D526BFC'><center id='4E3D526BFC'><tfoot id='4E3D526BFC'></tfoot></center><abbr id='4E3D526BFC'><dir id='4E3D526BFC'><tfoot id='4E3D526BFC'></tfoot><noframes id='4E3D526BFC'>
      • <optgroup id='4E3D526BFC'><strike id='4E3D526BFC'><sup id='4E3D526BFC'></sup></strike><code id='4E3D526BFC'></code></optgroup>
        5. <b id='4E3D526BFC'><label id='4E3D526BFC'><select id='4E3D526BFC'><dt id='4E3D526BFC'><span id='4E3D526BFC'></span></dt></select></label></b><u id='4E3D526BFC'></u>
          <i id='4E3D526BFC'><strike id='4E3D526BFC'><tt id='4E3D526BFC'><pre id='4E3D526BFC'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-28 02:09:40 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：6
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Neurocrine congenital adrenal hyperplasia trial succeeds
                                
                            
          Next article：  
                                      
                                          How to save PrEP access — and even expand it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles